ENHERTU cuts breast cancer recurrence risk by 53% in post-surgery trial
Tweet Send to a Friend
ENHERTU reduced the risk of disease recurrence or death by 53% compared to T-DM1 in patients with high-risk HER2 positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
